l'institut du thorax, Inserm U1087, CHU Nantes, Nantes Université
Nantes
Joined September 2018
- Tweets374
- Following225
- Followers201
- Likes2.1K
Capoulade Romain retweeted
📢 Rejoignez notre équipe à l’@HopitalPompidou
Nous recherchons un Technicien de Laboratoire en Hématologie
🔬 Environnement innovant
💡 Formations & évolutions possibles
🎯 Missions variées en cytologie et hémostase
📍 Paris 15e
📩 Contactez : [email protected]
Capoulade Romain retweeted
Please check LPa on all aortic stenosis patients.
Lipoprotein(a) is one of the strongest risk factors for aortic stenosis.
Results of our new meta-analysis, just out in @JAMACardio, reveal that Lp(a) is also strongly associated with aortic stenosis *progression*!
Thanks to everyone who contributed.
jamanetwork.com/journals/jam…
Capoulade Romain retweeted
Encore une très belle édition du weekend translationnel co-organisé avec le @CCF_cardio
Merci à tous les orateurs pour leurs disponibilités et la richesse des échanges !
Vivement l'année prochaine !!
@GRRC_SFCardio @SFCardio
Capoulade Romain retweeted
A large retrospective cohort study supports the need for sex-specific evaluation and management of patients even in the early stages of aortic stenosis: cle.clinic/3t4FGom
Capoulade Romain retweeted
L'appel d'offre pour les allocations de fin de thèse est ouvert !
Application avant le vendredi 5 avril minuit.
Don't hesitate to apply and join our group.
We are looking for a highly motivated postdoc with understanding and expertise in cell biology, biochemistry and molecular analyses.
New post doc position in cell biology / CV diseases available @institut_thorax in the group of @CapouladeR
Capoulade Romain retweeted
Flow rate and DI matter in AS, check out our paper with @JudyHungMD @TimChurchillMD @CapouladeR @PPibarot
American Journal of Cardiology ajconline.org/article/S0002-…
#EchoFirst
See our recent paper on the aortic valve phenotype in patients with FLNA variants.
Mutated patients present frequent aortic valve disease and worse outcomes, and a higher prevalence of bicuspid aortic valve.
heart.bmj.com/content/early/…
Capoulade Romain retweeted
Voici venu le temps de soumettre votre abstract pour notre prochain PC à Lille du 1er au 3 Juillet 2024 @JeremyFauconni1 @RA_GRRC @SFCardio
pc2024.process.y-congress.co…
Merci @FHU_CARNAVAL pour l'invitation ! Une très belle journée qui montre la force scientifique de votre réseau ! Félicitations !!
Notre journée scientifique se termine avec notre dernier conférencier @CapouladeR de l'@institut_thorax qui nous fait l'honneur d'une conférence sur la physiopathologie du rétrécissement aortique calcifié.
@NantesUniv
Capoulade Romain retweeted
Notre journée scientifique se termine avec notre dernier conférencier @CapouladeR de l'@institut_thorax qui nous fait l'honneur d'une conférence sur la physiopathologie du rétrécissement aortique calcifié.
@NantesUniv
Capoulade Romain retweeted
This is the 5-years analysis of the PARTNER 3 that we presented at TCT and published in NEJM 2 days ago.
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years | NEJM nejm.org/doi/pdf/10.1056/NEJ…
Capoulade Romain retweeted
Just presented at TCT and published in Circulation: Primary results of the VIVA trial: Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial | Circulation ahajournals.org/doi/10.1161/…
Capoulade Romain retweeted
Important paper published in JACC on The Mortality Burden of Untreated Aortic Stenosis pubmed.ncbi.nlm.nih.gov/3787…
Capoulade Romain retweeted
Presented today at #TCT2023:
Among patients at low surgical risk who underwent TAVR or surgery, there was no apparent difference between groups in the composite end point of death, stroke, or rehospitalization at 5 years.
Full PARTNER 3 trial results: nej.md/3FpxQbP
Capoulade Romain retweeted
EVOLUT LOW RISK TRIAL 4-Yr Results:
🎯 TAVR patients maintain durable outcomes & better hemodynamics than SAVR over 4 years.
🎯 26% reduced hazard for death or disabling stroke in Evolut TAVR vs SAVR, with diverging curves.
🎯 Lower mean gradients & higher EAs with Evolut TAVR at all check-ins.
🎯 85% of TAVR patients had minimal PVR; no significant group difference for moderate or greater PVR.
🎯 Valve performance indicators like high gradients & severe PPM favored TAVR, with similar thrombosis rates.
#TCT2023
